Setting new standards in information exchange for the pharmaceutical and biotech industry
Clinical Research as a Care Option (CRAACO) Recap
April 5, 2017
The Conference Forum presented an afternoon program on April 4th dedicated to Clinical Research as a Care Option (CRAACO).
How can CRAACO become a reality? To find out, let’s take a look at the highlights from CRAACO:
- Keynote Speaker Panel Explores Bridging Healthcare to Life Science
The CRAACO portion of the CTC conference launched with a keynote speaker discussion about how to bridge healthcare to life science.
Panel discussion participants included:
Jennifer Byrne, Founder, Greater Gift Initiative
John McConnell, MD, CEO, Wake Forest University Medical Center
Tom Pike, Life Science Advisor, Former CEO, Quintiles
According to McConnell, it is paramount for healthcare organizations to think about all aspects of the healthcare system relative to CRAACO. By doing so, these organizations can identify clinical trial problems and address such issues before they escalate.
“We need to think about making that whole system of clinical trials as a care option work,” McConnell said.
In addition, effective data management and education are key tenets to link healthcare to life science, McConnell stated.
“We need more data,” he noted. “More education and support are needed to make clinical trial a valuable experience for organizations and patients.”
- Healthcare Experts Discuss Accountable Care Organization (ACO) and Clinical Research As a Counter Measure
Healthcare is shifting toward a value-based system where quality, cost and experience are transparent to the patient. As such, the link between clinical research and population health and value is becoming increasingly important to healthcare organizations and patients alike.
Several healthcare leaders discussed how organizations are using clinical research in conjunction with their ACO to drive value during a CRAACO panel discussion that featured insights from:
Jeff James, CEO, Wilmington Health
Kenneth Bilger, CEO, Christie Clinic
Robert Matthews, President and CEO, Medisync
Matthews defined value as “the amount a group is paid for medical services and/or number of patients that can be gained with access to care.” He also indicated the value-payment model offers enhanced measurement and transparency – both of which are exceedingly valuable for patients and healthcare organizations.
Data may transform the way that healthcare organizations analyze value as well, Matthews stated. If healthcare organizations embrace data management and discover ways to get doctors to engage on data, these organizations may be able to optimize the value of their clinical research efforts.
- Leadership Panels Analyzes Value-Based Healthcare Delivery
What is value-based healthcare, and how can it help deliver improved patient outcomes? Healthcare experts explored these topics as part of a CRAACO panel discussion that included insights from:
Meredith Alger, Healthcare Researcher, Program Manager, Harvard Business School
Christina Akerman, MD, President, International Consortium of Health Outcome Measurements (ICHOM)
Toyin Okanlawon, MD, Senior Researcher, Harvard Business School, Institute for Strategy & Competitiveness
How value-based healthcare can be delivered often is debated, according to Okanlawon. But healthcare organizations cannot debate the importance of healthcare quality and the accountability factors associated with it.
“Value is not synonymous with quality,” Okanlawon said. “Value embeds itself with accountability. … At the end of the day, we’re all going to disagree on how to measure costs. But we can’t really disagree on whether someone is dead or alive.”
Furthermore, healthcare organizations must prioritize value-based outcomes over costs, Akerman stated. This approach will enable healthcare organizations to define patient standards and ensure both organizations and patients can optimize the value of healthcare treatments.
- Healthcare Leaders Discuss Data Science for Clinical Research and Care Delivery
The final CRAACO leadership panel discussion examined opportunities for life science organizations to create value from data science and align incentives to help physicians conduct clinical research, improve data quality and preserve patient safety.
Discussion participants included:
Craig Lipset, Head of Clinical Innovation, R&D, Pfizer
William Crown, PhD, Chief Science Officer, Optum Labs
Kenneth Mandl, MD, Director, Computational Health Informatics Program/Professor, Boston Children’s Hospital/Harvard Medical School
Kyu Rhee, MD, Chief Health Officer, IBM
Data and analytics together drive healthcare enablement. These technologies empower healthcare organizations with insights into patient behaviors and trends and can help these organizations uncover meaningful insights to drive CRAACO.
“There are many hooks into data and analytics, and there is also a decision support network developing from it,” Mandl said.
The role of technology in advancing key healthcare insights continues to expand, Rhee indicated.
Cloud, content and cognitive technologies help healthcare organizations gain insights from a large assortment of data. Yet collaborations may have the greatest impact on healthcare organizations because they allow these organizations to look beyond the healthcare setting and find innovative ways to engage all stakeholders, Rhee said.
Thank you to everyone who made the CRAACO event possible, especially Eli Lilly and Company and PMG Research, Inc.